Millennium, Bristol-Myers deal

MLNM’s Millennium Predictive Medicine Inc. subsidiary will provide pharmacogenomic services to Bristol-Myers to identify and validate genetic markers that can be used to predict patient response to Bristol-Myers’ oncology therapeutic products in development and on the market. Predictive Medicine will receive up to $32 million in license fees, annual fees and research funding over five years, and is eligible for milestone payments and royalties. ...